L'Institut de NeuroPhysiopathologie (INP) est un centre d'excellence pour la formation et la recherche qui allie la recherche fondamentale et translationnelle pour étudier l'organisation, la fonction et l'interaction des cellules neurales, les bases moléculaires et cellulaires des principales maladies du cerveau, et développer des stratégies de thérapies cellulaires et moléculaires innovantes.
La PFNT (Plateforme NeuroTimone) est un ensemble cohérent d'outils d'exploration en neurobiologie permettant des investigations aux échelles moléculaires, cellulaires et intégrées.
Santiago Rivera represented the INP on the 1st Congress of the 7 CoENs (International Neetwork of Centers of Excellence in Neurodegeneration) held in Montpellier on October 18 and 19, 2018, endorsed by AVIESAN: Bordeaux, Grenoble, Lille, Montpellier, Marseille, Paris and Toulouse. He gave a lecture in the CoEN Pathfinder laureates’ session entitled MT-MMPs at the crossroads of amyloidogenesis and neuroinflammation in Alzheimer's disease.
The Emergence project entitled “Tau, from Alzheimer disease to glioblastoma, evolution of a prognostic marker” was selected by the Canceropole PACA to be founded by the GEFLUC (groupement des entreprises françaises dans la lutte contre le cancer). Team 9 has a long-time expertise on Tau and this grant will be used to complete the identification of the kinases responsible for Tau phosphorylation in glioblastoma.
Photo from the GEFLUC
On September 12, over 300 students, teachers, researchers, clinicians and entrepreneurs participated in the launch of NeuroSchool, the school that unifies and harmonizes the teachings of the third year of the bachelor's degree (Neuroscience path), the master's degree and the PhD program in neuroscience. Funded by the National Research Agency and the A*Midex Foundation, NeuroSchool will benefit from a funding of approximately 10 million euros (over 10 years).
Michel Khrestchatisky gave a talk on the ongoing projects of his group and biotechnology partner Vect-Horus, also member of the ECMED consortium, while Grigorios Kyriatzis presented results of his ongoing PhD project.
#EUROTAU 2018 - European scientists involved in Tau research met in Lille to exchange new ideas and hypotheses on physiological and pathological roles of tau proteins (26-27th April 2018). François Devred gave one of the 38 selected talks in which he presented a new reversible oligomerization of tau protein evidenced in INP team 9, which could have a protective physiological role and prevent pathological aggregation of tau in neurodegenerative diseases. Next edition of EuroTau will be in 2020.
Photo © Valérie Buée Scherrer
Congratulations to all the CNRS team for running the Marseille-Cassis race two weekends ago, and especially to Claude Villard (7th from the left, top row), INP team 9 and PINT facility member who ran this semi-marathon in 1 hour and 48 minutes.
Next year, let's make a whole INP team (as usual, the race will take place on the last Sunday of October)!
For more information, head to the race's official website.
Lors de la soirée des NeuroStories qui a eu lieu lundi 7 octobre à la faculté de médecine, Anne-Marie François Bellan a livré une prestation remarquée sur la façon dont notre corps vibre au rythme de chronomètres internes appelés horloges circadiennes. Elle a également expliqué comment l’horloge moléculaire utilise des petits corpuscules et l’espace de la cellule pour faire rythmer nos gènes. La vidéo de son intervention ainsi que celles des six autres orateurs seront disponibles très prochainement.
The cIMPACT-NOW Working Committee is the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. cIMPACT-NOW was created in late 2016 —following publication of the 2016 Updated 4th Edition of the World Health Organization (WHO) Classification of Tumours of the Central Nervous System— to provide a forum to evaluate and recommend proposed changes to future CNS tumor classifications.
During the 14th EANO annual meeting 3 members of INP team #8 presented their work on Glioma in a plenary conference «CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDHmutant gliomas» Dominique Figarella Branger, a short talk «Plasmatic differential scanning fluorimetry profiles discriminate glioma patients from healthy controls» Emeline Tabouret and two posters «P11.06: Non epigenetic effect of vorinostat
Nadia Merad Coliac, designer plasticienne, a rejoint l’équipe NOSE (Nasal Olfactory Stemness and Epigenesis) de l’INP, comme chercheuse associée. À la croisée de plusieurs disciplines, elle développe une réflexion et une œuvre expérimentale art et science, dans le domaine de la bioluminescence. Elle envisage une application thérapeutique dans les troubles du spectre autistique (TSA).
Many members of the INP attended the annual Canceropole PACA meeting in the Palais des Congrès of St Raphaël on the 4th and 5th of july. In the frame of the translational research call, F. Devred (INP team 9) & E. Tabouret (INP team 8) presented the results and perspective of their project "Next generation plasma profiling of gliomas using nanoDSF: toward a new prognostic and monitoring tool"
INP team 8 and 9 and PINT members being part of the French Microtubule Network, several members presented their work at the 4th French Microtubule Network gathering in Rennes on the 1srt and 2nd july 2019, in the "Microtubules and their regulators : new therapeutic targets" session and the "Microtubules, assembly and regulation" session.
An article entitled "Le CNRS et Aix-Marseille Université signent un accord avec la PME Vect-Horus sur la propriété intellectuelle", published in the CNRS Innovation Letter of 20 June 2019 and relayed by the INSB site, features the agreement signed by CNRS, AMU and Vect-Horus establishing the intellectual property rights regime and the exploitation of patents.
Our last work on IAPs : "Inhibitor of Apoptosis Proteins (IAPs) Determines Glioblastoma Stem‐Like Cell Fate in an Oxygen‐Dependent Manner" is now published in Stem Cells. We highlighted that pharmacological inhibition of IAPs by Smac mimetic GDC-0152 was able to decrease glioblastoma stem-like cells viability in hypoxia by decreasing cell proliferation and increasing apoptosis through ATR and TNFα pathways
Aix Marseille Université | All rights reserved - Legal notice
